For Healthcare Professionals Only.
The COVID-19 pandemic has brought to light the heightened vulnerability of certain demographic groups, particularly elderly individuals, and patients with type 2 diabetes mellitus (T2DM). These cohorts face not only increased susceptibility to infections but also heightened risks of severe illness and adverse health outcomes. Recognising the urgent need to safeguard these vulnerable populations, researchers have explored an innovative strategy utilising a novel microbiome immunity formula consisting of both pre- and probiotics, SIM01, to mitigate such risks following the pandemic.
Login to read more
